Literature DB >> 16166076

Use of antioxidants during chemotherapy and radiotherapy should be avoided.

Gabriella M D'Andrea1.   

Abstract

Many patients being treated for cancer use dietary supplements, particularly antioxidants, in the hope of reducing the toxicity of chemotherapy and radiotherapy. Some researchers have claimed, furthermore, that antioxidants also increase the effectiveness of cytotoxic therapy and have explicitly recommended their use. However, mechanistic considerations suggest that antioxidants might reduce the effects of conventional cytotoxic therapies. Preclinical data are currently inconclusive and a limited number of clinical studies have not found any benefit. Clinicians should advise their patients against the use of antioxidant dietary supplements during chemotherapy or radiotherapy. Such caution should be seen as the standard approach for any unproven agent that may be harmful.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166076     DOI: 10.3322/canjclin.55.5.319

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  56 in total

1.  Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians' Health Study.

Authors:  Danielle N Margalit; Julie L Kasperzyk; Neil E Martin; Howard D Sesso; John Michael Gaziano; Jing Ma; Meir J Stampfer; Lorelei A Mucci
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-11       Impact factor: 7.038

2.  Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort.

Authors:  Heather Greenlee; Marilyn L Kwan; Lawrence H Kushi; Jun Song; Adrienne Castillo; Erin Weltzien; Charles P Quesenberry; Bette J Caan
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

Review 3.  Diet and prostate cancer: mechanisms of action and implications for chemoprevention.

Authors:  Vasundara Venkateswaran; Laurence H Klotz
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

Review 4.  Which botanicals or other unconventional anticancer agents should we take to clinical trial?

Authors:  Andrew J Vickers
Journal:  J Soc Integr Oncol       Date:  2007

Review 5.  Putting Integrative Oncology Into Practice: Concepts and Approaches.

Authors:  Shelly Latte-Naor; Jun J Mao
Journal:  J Oncol Pract       Date:  2019-01       Impact factor: 3.840

6.  Is the combinational administration of doxorubicin and glutathione a reasonable proposal?

Authors:  Bo-Yu Shen; Chong Chen; Yang-Fan Xu; Jia-Jia Shen; Hui-Min Guo; Hao-Feng Li; Xi-Nuo Li; Dian Kang; Yu-Hao Shao; Zhang-Pei Zhu; Xiao-Xi Yin; Lin Xie; Guang-Ji Wang; Yan Liang
Journal:  Acta Pharmacol Sin       Date:  2018-09-14       Impact factor: 6.150

7.  Antioxidants and Other Micronutrients in Complementary Oncology.

Authors:  Uwe Gröber
Journal:  Breast Care (Basel)       Date:  2009-02-20       Impact factor: 2.860

Review 8.  How to design a phase I trial of an anticancer botanical.

Authors:  Andrew J Vickers
Journal:  J Soc Integr Oncol       Date:  2006

Review 9.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

10.  Sulforaphane and related mustard oils in focus of cancer prevention and therapy.

Authors:  Ingrid Herr; Vladimir Lozanovski; Philipp Houben; Peter Schemmer; Markus W Büchler
Journal:  Wien Med Wochenschr       Date:  2012-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.